-
Something wrong with this record ?
HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control
M. Douša, M. Slavíková, T. Kubelka, J. Černý, P. Gibala, J. Zezula,
Language English Country England, Great Britain
Document type Journal Article, Validation Study
- MeSH
- Chemical Fractionation instrumentation methods MeSH
- Chemistry, Pharmaceutical methods MeSH
- Spectrometry, Mass, Electrospray Ionization instrumentation methods MeSH
- Drug Contamination prevention & control MeSH
- Chenodeoxycholic Acid analogs & derivatives analysis chemistry MeSH
- Limit of Detection MeSH
- Drug Compounding instrumentation methods MeSH
- Reproducibility of Results MeSH
- Quality Control * MeSH
- Sensitivity and Specificity MeSH
- Spectrophotometry, Ultraviolet instrumentation methods MeSH
- Chromatography, High Pressure Liquid instrumentation methods MeSH
- Publication type
- Journal Article MeSH
- Validation Study MeSH
An HPLC method with UV and electrospray ionization - mass spectrometry (ESI-MS) detection was developed for the separation and determination of obeticholic acid (OBE) and its related compounds in development process and quality control. OBE and its related compounds were classified into three major group based on the mass spectra profiles: (A) those containing a hydroxyl group at position 3 and 7, (B) those containing a hydroxyl group and/or carbonyl group at position 3, hydrogen, ethyl or ethylidene group at position 6 and a hydroxyl group and/or carbonyl group at position 7, and (C) those containing carbonyl groups at position 3 and 7. ESI-MS ionization of OBE and its related compounds often produced intense adduct ions [M+H+98]+ and/or [M+H+196]+ that were identified as the adduct ions of phosphoric acid ([M+H+H3PO4]+ and [M+H+2H3PO4]+) originating from the mobile phase. The separation on HPLC system was accomplished using stationary phase based on XSelect CSH C18 (3.0×150mm×2.5μm) and a linear gradient elution using acetonitrile and 0.05% of o-phosphoric acid. The condition of chromatographic system was set as follows: flow rate 0.7mL/min, temperature 45°C and UV detection at 192nm. The separation of the 19 compounds was finished in less than 18min (including equilibration time). The HPLC/UV method was partially validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines in terms of repeatability, selectivity, linearity and limit of quantification and detection.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033577
- 003
- CZ-PrNML
- 005
- 20181009110307.0
- 007
- ta
- 008
- 181008s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2017.11.018 $2 doi
- 035 __
- $a (PubMed)29126083
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Douša, Michal $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz.
- 245 10
- $a HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control / $c M. Douša, M. Slavíková, T. Kubelka, J. Černý, P. Gibala, J. Zezula,
- 520 9_
- $a An HPLC method with UV and electrospray ionization - mass spectrometry (ESI-MS) detection was developed for the separation and determination of obeticholic acid (OBE) and its related compounds in development process and quality control. OBE and its related compounds were classified into three major group based on the mass spectra profiles: (A) those containing a hydroxyl group at position 3 and 7, (B) those containing a hydroxyl group and/or carbonyl group at position 3, hydrogen, ethyl or ethylidene group at position 6 and a hydroxyl group and/or carbonyl group at position 7, and (C) those containing carbonyl groups at position 3 and 7. ESI-MS ionization of OBE and its related compounds often produced intense adduct ions [M+H+98]+ and/or [M+H+196]+ that were identified as the adduct ions of phosphoric acid ([M+H+H3PO4]+ and [M+H+2H3PO4]+) originating from the mobile phase. The separation on HPLC system was accomplished using stationary phase based on XSelect CSH C18 (3.0×150mm×2.5μm) and a linear gradient elution using acetonitrile and 0.05% of o-phosphoric acid. The condition of chromatographic system was set as follows: flow rate 0.7mL/min, temperature 45°C and UV detection at 192nm. The separation of the 19 compounds was finished in less than 18min (including equilibration time). The HPLC/UV method was partially validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines in terms of repeatability, selectivity, linearity and limit of quantification and detection.
- 650 _2
- $a chemická frakcionace $x přístrojové vybavení $x metody $7 D005591
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a kyselina chenodeoxycholová $x analogy a deriváty $x analýza $x chemie $7 D002635
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $x přístrojové vybavení $x metody $7 D002851
- 650 _2
- $a příprava léků $x přístrojové vybavení $x metody $7 D004339
- 650 _2
- $a kontaminace léku $x prevence a kontrola $7 D004340
- 650 _2
- $a limita detekce $7 D057230
- 650 12
- $a řízení kvality $7 D011786
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a hmotnostní spektrometrie s elektrosprejovou ionizací $x přístrojové vybavení $x metody $7 D021241
- 650 _2
- $a spektrofotometrie ultrafialová $x přístrojové vybavení $x metody $7 D013056
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a validační studie $7 D023361
- 700 1_
- $a Slavíková, Markéta $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Kubelka, Tomáš $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Černý, Josef $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Gibala, Petr $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Zezula, Josef $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 149, č. - (2018), s. 214-224
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29126083 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181009110755 $b ABA008
- 999 __
- $a ok $b bmc $g 1340211 $s 1030571
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 149 $c - $d 214-224 $e 20171104 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20181008